Targeted Oncology1h
FDA Clears Investigational New Drug Application for REC-4539 in SCLC
The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...
Targeted Oncology1h
Amezalpat Gains FDA Orphan Drug Status in HCC
The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...
Targeted Oncology4h
FDA Grants B7-H3–Targeted ADC Breakthrough Status in Osteosarcoma
The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...
Targeted Oncology6h
FDA Fast Tracks Abenacianine for Lung Cancer Surgery
Abenacianine, a tumor-targeted fluorescent imaging agent, received fast track designation from the FDA after demonstrating ...
Targeted Oncology21h
An Investigator-Initiated Study of Loncastuximab Tesirine Plus Rituximab for the Treatment of R/R FL
A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier ...
Targeted Oncology22h
Options for MRD Testing Affect Patient Treatment Plan in Lung Cancer
Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.